Anixa Biosciences (ANIX) Q3 2026 earnings summary

Executive summary

• Focused on developing cancer vaccines and CAR-T therapeutics, with ongoing clinical trials in breast and ovarian cancer and early-stage research in additional cancer types.

• No revenue generated from therapeutics or vaccine programs to date; revenue historically from technology licensing and patent settlements.

• Collaboration with leading research institutions and government grants supports R&D while conserving cash.

Financial highlights

• Net loss for the quarter ended July 31, 2026 was $2.6 million, compared to $2.3 million in the same quarter last year.

• Net loss for the nine months ended July 31, 2026 was $7.7 million, down from $8.2 million year-over-year.

• No revenue recognized in the current or prior year periods.

• Cash, cash equivalents, and short-term investments totaled $13.9 million as of July 31, 2026, down from $15.2 million at October 31, 2025.

• Raised $4.8 million net through an at-the-market equity offering during the nine months ended July 31, 2026.

Outlook and guidance

• Management expects existing cash and investments to fund operations for at least the next twelve months.

• No near-term revenue expected from therapeutics or vaccine programs; focus remains on advancing clinical trials and research collaborations.